BRAF and glioblastoma: Based on multiomics studies, EGFR, vascular endothelial growth factor (VEGFR), platelet-derived growth factor receptor (PDGFR), BRAF V600E mutation, histone 3 K27M (H3K27M) mutations, and neurotrophic tyrosine receptor kinase (NTRK) fusions are potential therapeutic targets in GBM, and clinical trials and clinical application are recommended in the future (8).